US · ARWR
Arrowhead Pharmaceuticals, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Pasadena, CA 91105
- Website
- arrowheadpharma.com
Price · as of 2025-09-30
$74.81
Market cap 8.86B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $3,580.08 | +4,685.56% |
| Intrinsic Value(DCF) | $60,895.38 | +81,300.05% |
| Graham-Dodd Method(GD) | $3.42 | -95.42% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $5.06 | $59.07 | $3.33 | $0.00 | $18.21 |
| 2012 | $2.13 | $29.45 | $0.00 | $0.00 | $76.15 |
| 2013 | $8.16 | $35.45 | $0.18 | $0.00 | $0.00 |
| 2014 | $5.73 | $25.02 | $2.23 | $0.00 | $37.42 |
| 2015 | $5.64 | $35.96 | $0.20 | $0.00 | $0.00 |
| 2016 | $1.35 | $26.89 | $0.11 | $0.00 | $64.22 |
| 2017 | $3.45 | $3,012.55 | $2,547.15 | $0.00 | $0.00 |
| 2018 | $13.13 | $30.43 | $0.49 | $0.00 | $24.97 |
| 2019 | $67.27 | $234.87 | $9,591.35 | $6.23 | $660.94 |
| 2020 | $74.06 | $62.66 | $15.23 | $0.39 | $31.56 |
| 2021 | $70.07 | $73.80 | $255.26 | $0.00 | $0.00 |
| 2022 | $30.24 | $44.70 | $384.00 | $0.00 | $0.00 |
| 2023 | $23.95 | $26.86 | $5.42 | $0.00 | $0.00 |
| 2024 | $23.61 | $25.19 | $0.00 | $0.00 | $431.32 |
| 2025 | $61.44 | $3,580.08 | $588.76 | $3.42 | $0.00 |
AI valuation
Our deep-learning model estimates Arrowhead Pharmaceuticals, Inc.'s (ARWR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $3,580.08
- Current price
- $74.81
- AI upside
- +4,685.56%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$60,895.38
+81,300.05% upside
Graham-Dodd
$3.42
-95.42% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ARWR | Arrowhead Pharmaceuticals… | $74.81 | 8.86B | +4,686% | +81,300% | -95% | — | 272.90 | 17.63 | 9.91 | 46.50 | — | 17.90 | 97.12% | 11.86% | -0.20% | 9.24% | 42.67% | 2.39% | 0.79 | 1.10 | 4.86 | 4.74 | 0.85 | -9976.00% | 2325815.00% | -12596.00% | 1.91% | 0.92 | 116.49% | 0.00% | 0.00% | 7.42% | 77.94 | 48.86 | 9.24 | 5.43 |
| ACLX | Arcellx, Inc. | $113.79 | 6.58B | -42% | — | — | — | -28.05 | — | — | -31.38 | -27.10 | — | 0.00% | — | — | -100.68% | 644.58% | -39.69% | — | -10.45 | — | — | 0.00 | 10350.00% | -10000.00% | 11938.00% | -3.31% | — | 541.60% | 0.00% | 0.00% | 0.02% | -25.37 | -30.21 | — | — |
| ALKS | Alkermes plc | $30.10 | 4.97B | +85% | -49% | -41% | -85% | 20.62 | 2.74 | 3.38 | 13.49 | — | 2.87 | 86.31% | 17.21% | 16.37% | 14.72% | 20.15% | 10.64% | 0.04 | 20.69 | 2.06 | 1.70 | -1.57 | -3410.00% | -525.00% | -9987.00% | 0.01% | 0.00 | 0.05% | 0.00% | 0.00% | 6.08% | 17.58 | 8571.26 | 3.02 | 5.27 |
| AXSM | Axsome Therapeutics, Inc. | $163.89 | 8.38B | -38% | +8,512% | — | — | -45.19 | 93.74 | 12.96 | -48.76 | — | 231.63 | 92.56% | -26.51% | -28.69% | -252.11% | 574.69% | -29.11% | 2.73 | -25.81 | 1.55 | 1.44 | 0.49 | -3856.00% | 6555.00% | -2741.00% | -1.13% | -0.25 | 318.10% | 0.00% | 0.00% | 0.00% | -48.43 | -87.74 | 12.84 | 6.09 |
| CRSP | CRISPR Therapeutics AG | $60.14 | 5.77B | -40% | -46% | — | +738% | -9.40 | 2.84 | 1556.91 | -7.08 | -19.15 | 2.84 | -6537.01% | -16191.40% | -16569.77% | -30.18% | -191.73% | -25.81% | 0.21 | — | 13.32 | 13.25 | -0.07 | 4908.00% | -8997.00% | 13911.00% | -6.33% | -2.31 | -116.70% | 0.00% | 0.00% | 0.00% | -6.83 | -11.23 | 1106.51 | 8.49 |
| KRYS | Krystal Biotech, Inc. | $275.64 | 8.06B | -24% | -34% | -72% | +4% | 36.57 | 6.14 | 19.25 | 39.75 | 28.57 | 6.14 | 92.61% | 41.45% | 52.64% | 18.91% | 42.60% | 17.14% | 0.01 | — | 9.95 | 9.28 | -2.90 | 12800.00% | 3394.00% | 5851.00% | 2.52% | 1.95 | 49.90% | 0.00% | 0.00% | 1.99% | 41.37 | 35.32 | 17.15 | 40.89 |
| KYMR | Kymera Therapeutics, Inc. | $91.35 | 7.31B | -43% | -53% | -100% | -68% | -24.42 | 4.81 | 193.97 | -22.56 | -102.50 | 4.81 | 100.00% | -891.33% | -794.39% | -25.78% | -55.98% | -22.89% | 0.05 | -1403.21 | 10.47 | 10.19 | 0.91 | 2383.00% | -1672.00% | 1302.00% | -3.08% | -2.80 | -37.55% | 0.00% | 0.00% | 3.19% | -19.57 | -29.18 | 174.43 | 27.01 |
| MTSR | Metsera, Inc. | $70.50 | 7.43B | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | -108.40% | 1345.61% | -67.48% | 0.03 | -1008.22 | 5.34 | 5.24 | 1.57 | 10947.00% | — | 18254.00% | — | -1.49 | 625.73% | — | 0.00% | — | — | — | — | — |
| PCVX | Vaxcyte, Inc. | $61.74 | 8.86B | — | — | — | — | -11.00 | 3.14 | — | -9.58 | -22.85 | 3.14 | 0.00% | — | — | -25.59% | -61.93% | -23.38% | 0.09 | — | 7.91 | 7.81 | -0.07 | 4816.00% | — | 4089.00% | -7.93% | -3.19 | -44.87% | 0.00% | 0.00% | 0.00% | -7.69 | -10.61 | — | 12.61 |
| PTCT | PTC Therapeutics, Inc. | $68.19 | 5.47B | +340% | +35% | -42% | +1,382% | 7.73 | -25.71 | 3.05 | 4.31 | — | -7.80 | 95.85% | 49.49% | 39.44% | -104.75% | -117.79% | 29.58% | -2.40 | 5.63 | 2.35 | 2.20 | -0.55 | -26448.00% | 11451.00% | -48603.00% | 13.31% | 0.73 | -98.57% | 0.00% | 0.00% | 41.37% | 4.47 | 5.45 | 2.21 | 1.69 |
| TGTX | TG Therapeutics, Inc. | $30.09 | 4.78B | +200% | +4,085% | -34% | +845% | 9.49 | 6.55 | 6.88 | 33.25 | 0.54 | 6.55 | 83.62% | 20.01% | 72.56% | 102.75% | 36.31% | 54.50% | 0.01 | 4.61 | 4.10 | 2.91 | -0.58 | 174667.00% | 8732.00% | -3840.00% | -0.59% | -0.16 | -7.36% | 0.00% | 0.00% | 5.57% | 33.32 | -164.45 | 6.67 | 6.21 |
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
- CEO
- Christopher R. Anzalone
- Employees
- 609
- Beta
- 1.22
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($60,895.38 ÷ $74.81) − 1 = +81,300.05% (DCF, example).